Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.46), $0.51 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $23.6 million versus the consensus estimate of $25.74 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.